Home » Market News » DirectorsTalk Highlights » Altered gut microbiota in ALS patients could drive digestive problems
Oxford BioDynamics

Altered gut microbiota in ALS patients could drive digestive problems

People with amyotrophic lateral sclerosis (ALS) have an altered composition of their gut microbial community, with an increase in harmful microbes and a decrease in beneficial microorganisms, according to a new small study.

This altered gut microbiota could drive digestive problems in those with ALS, the researchers said.

The study, “Intestinal microbiota composition in patients with amyotrophic lateral sclerosis,” appeared in the Chinese Medical Journal.

Oxford Biodynamics PLC (LON:OBD) was spun out from Oxford University in June 2007 with the aim of translating fundamental scientific advances into a commercialised platform technology and a new generation of biomarkers for cancer and other diseases. OBD has been granted a substantial funding award from Innovate UK to develop and validate diagnostic, prognostic and predictive EpiSwitch™ biomarkers for ALS.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.